Product Description: Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
CAS Number: 2988886-91-3
Molecular Weight: N/A
Research Area: Cancer
Target: CD3;TNF Receptor